Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

GlaxoSmithKline and Impax to Develop Late-Stage Compound for Parkinson’s Disease

By Pharmaceutical Processing | December 16, 2010

GlaxoSmithKline and Impax Pharmaceuticals, the brand products division of Impax
Laboratories, Inc., today announced an agreement for the development
and commercialization of IPX066, Impax’s novel extended release
carbidopa-levodopa product, outside the United
States and Taiwan. IPX066, an investigational
product under development for the treatment of Parkinson’s Disease (PD), is currently
in Phase III clinical trials.

Under the terms of the agreement, GSK will receive an
exclusive license to sell IPX066 throughout the world except in the U.S. and Taiwan. Impax will receive an $11.5
million upfront payment and is eligible to receive potential payments of up to
$175 million upon the successful achievement of development and
commercialization milestones. Impax will also receive tiered, double-digit
royalty payments on GSK sales of IPX066. Impax will manufacture and supply IPX066
to GSK.

Impax will complete the current Phase III program for
IPX066, which includes the recently completed APEX-PD trial in early PD. The
results from the remaining Phase III study program are expected to be available
in 2011. In the U.S.,
Impax expects to file a New Drug Application for Parkinson’s Disease in late
2011 and will be responsible for commercialization. In other regions, excluding
Taiwan,
GSK will be responsible for further development and registration of IPX066 and
commercialization of the product in those markets. A team structure with
representatives from both companies is being established to enable effective
coordination of planned global regulatory and commercialization activities.

“We are very pleased to announce this development and
collaboration agreement with GSK, which is a significant milestone in the development
of Impax Pharmaceuticals and an important achievement in the planned global
commercialization for IPX066 for the treatment of Parkinson’s Disease,”
stated Michael Nestor, President of Impax Pharmaceuticals. “GSK is an
ideal partner for IPX066, combining global best-in-class development,
regulatory and commercial experience in Parkinson’s Disease, which will be an
asset in the successful commercialization of IPX066.” “We are excited
by the opportunity IPX066 represents to patients,” commented, Atul Pande,
senior vice president, Neurosciences
Medicines Development
Center, GSK. “There
is a significant need for a therapy which can improve on clinical symptom
management and control in Parkinson’s Disease. We look forward to collaborating
with Impax and hope to deliver an improved treatment option to the millions of
people living with this devastating disease.”  

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE